Patents by Inventor Tatsuro KANAKI

Tatsuro KANAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132827
    Abstract: A separation device for separating a solid separation target contained in a suspension obtained by suspension culture of adherent cells by using a fine scaffold material, and a separation method. The separation device has a separation chamber having a first chamber and a second chamber, and the first chamber and the second chamber are divided by a mesh structure for separation. The mesh structure for separation has mesh-holes with a predetermined size to suppress passage of the separation target, and a mesh structure for separation is configured in the separation chamber such that the liquid in the aforementioned suspension has a vertically upward directional component in the advancing direction of the liquid when the liquid passes through the mesh-holes.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 25, 2024
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Daisuke HATANAKA, Katsuhiko KIDA, Tatsuro KANAKI, Hisato HAYASHI
  • Publication number: 20240084296
    Abstract: The invention provides a single-stranded oligonucleotide represented by the formula (I), wherein X and Y hybridize by a first nucleotide sequence portion and a second nucleotide sequence portion. X is composed of 7 to 100 nucleotides, contains at least one modified-nucleotide, and has a first nucleotide sequence capable of hybridizing with a second oligonucleotide. Y is composed of 4 to 100 nucleotides, enables hybridization with the above-mentioned first oligonucleotide, and has a second nucleotide sequence containing at least one ribonucleotide. At least one of the nucleotide sequences X, Xz and Y has an antisense sequence capable of hybridizing with a target RNA. At least one of L, Lx and Ly is a linking group that contains a non-nucleotide structure.
    Type: Application
    Filed: February 1, 2023
    Publication date: March 14, 2024
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI, Masatoshi NIWA
  • Publication number: 20230383245
    Abstract: The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition having an effect of preventing sedimentation of cells and/or tissues, which is afforded by substantially retaining the cells and/or tissues, without substantially increasing the viscosity of the solution, by nanofibers which have been added to the solution and uniformly dispersed in the liquid medium, and the like.
    Type: Application
    Filed: August 8, 2023
    Publication date: November 30, 2023
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Hisato HAYASHI, Misayo OTANI, Koichiro SARUHASHI, Taito NISHINO, Takehisa IWAMA, Tatsuro KANAKI, Ayako AIHARA
  • Publication number: 20230203498
    Abstract: Provided is a single-stranded oligonucleotide that is capable of controlling a target gene with high efficiency and can be easily produced. The single-stranded oligonucleotide is represented by the formula X-L-Y wherein X and Y hybridize by a first nucleotide sequence portion and a second nucleotide sequence portion. X is composed of 7 to 100 nucleotides, contains at least one modified nucleotide, and has a first nucleotide sequence that is capable of hybridizing with a second oligonucleotide and contains at least four contiguous nucleotides recognized by RNase H. Y is composed of 4 to 100 nucleotides, and has a second nucleotide sequence that is capable of hybridizing with a second oligonucleotide and contains at least one ribonucleotide. At least one of nucleotide sequence X and nucleotide sequence Y has an antisense sequence capable of hybridizing with a target RNA. L is a group derived from a third oligonucleotide that is degraded under physiological conditions.
    Type: Application
    Filed: November 11, 2022
    Publication date: June 29, 2023
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI
  • Publication number: 20230183702
    Abstract: The invention provides a single-stranded oligonucleotide represented by the formula [Xz — Lx]m — X — Y — [Ly — Yz]n, wherein X is represented by Xa-Xb, Xa is coupled with Y, and Xb and Y hybridize. Xa is composed of 1 to 40 nucleotides and contains at least one modified-nucleotide. Xb is composed of 4 to 40 nucleotides and contains at least one modified-nucleotide. Y is composed of 4 to 40 nucleotides and contains at least one ribonucleotide. Xz and Yz are composed of 5 to 40 nucleotides and contain at least one modified-nucleotide. Nucleotide sequences X, Xz and Yz have an antisense sequence capable of hybridizing with a target RNA. Lx and Ly are composed of 0 to 20 nucleotides.
    Type: Application
    Filed: January 10, 2023
    Publication date: June 15, 2023
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI
  • Patent number: 11572558
    Abstract: The invention provides a single-stranded oligonucleotide represented by the formula (I), wherein X and Y hybridize by a first nucleotide sequence portion and a second nucleotide sequence portion. X is composed of 7 to 100 nucleotides, contains at least one modified-nucleotide, and has a first nucleotide sequence capable of hybridizing with a second oligonucleotide. Y is composed of 4 to 100 nucleotides, enables hybridization with the above-mentioned first oligonucleotide, and has a second nucleotide sequence containing at least one ribonucleotide. At least one of the nucleotide sequences X, Xz and Y has an antisense sequence capable of hybridizing with a target RNA. At least one of L, Lx and Ly is a linking group that contains a non-nucleotide structure.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 7, 2023
    Assignee: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke Iriyama, Hiroyuki Nakajima, Tatsuro Kanaki, Masatoshi Niwa
  • Patent number: 11555188
    Abstract: The invention provides a single-stranded oligonucleotide represented by the formula [Xz-Lx]m-X-Y-[Ly-Yz]n, wherein X is represented by Xa-Xb, Xa is coupled with Y, and Xb and Y hybridize. Xa is composed of 1 to 40 nucleotides and contains at least one modified-nucleotide. Xb is composed of 4 to 40 nucleotides and contains at least one modified-nucleotide. Y is composed of 4 to 40 nucleotides and contains at least one ribonucleotide. Xz and Yz are composed of 5 to 40 nucleotides and contain at least one modified-nucleotide. Nucleotide sequences X, Xz and Yz have an antisense sequence capable of hybridizing with a target RNA. Lx and Ly are composed of 0 to 20 nucleotides.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: January 17, 2023
    Assignee: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke Iriyama, Hiroyuki Nakajima, Tatsuro Kanaki
  • Patent number: 11530387
    Abstract: The present invention provides a method for producing a unilocular adipocyte including inducing differentiation into unilocular adipocytes of mesenchymal cells having differentiation potency into adipocytes by culturing the mesenchymal cells in suspension in a liquid medium composition capable of culturing cells or tissues in suspension, wherein the liquid medium composition contains a polymer compound having an anionic functional group that binds via a divalent metal cation to form a structure capable of suspending cells or tissues, and the method wherein the polymer compound is polysaccharide, preferably polysaccharide containing a glucuronic acid moiety, more preferably deacylated gellan gum, diutan gum or xanthan gum or a salt thereof.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: December 20, 2022
    Assignee: NISSAN CHEMICAL CORPORATION
    Inventor: Tatsuro Kanaki
  • Patent number: 11530409
    Abstract: Provided is a single-stranded oligonucleotide that is capable of controlling a target gene with high efficiency and can be easily produced. The single-stranded oligonucleotide is represented by the formula X-L-Y wherein X and Y hybridize by a first nucleotide sequence portion and a second nucleotide sequence portion. X is composed of 7 to 100 nucleotides, contains at least one modified nucleotide, and has a first nucleotide sequence that is capable of hybridizing with a second oligonucleotide and contains at least four contiguous nucleotides recognized by RNase H. Y is composed of 4 to 100 nucleotides, and has a second nucleotide sequence that is capable of hybridizing with a second oligonucleotide and contains at least one ribonucleotide. At least one of nucleotide sequence X and nucleotide sequence Y has an antisense sequence capable of hybridizing with a target RNA. L is a group derived from a third oligonucleotide that is degraded under physiological conditions.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: December 20, 2022
    Assignee: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke Iriyama, Hiroyuki Nakajima, Tatsuro Kanaki
  • Publication number: 20220364050
    Abstract: A method for producing a medium composition for suspension culture of an adherent cell, including the following steps: (i) a step of making an extracellular matrix carried on a nanofiber composed of water-insoluble polysaccharides, (ii) a step of adding the extracellular matrix-carrying nanofiber obtained in step (i) to a medium is provided by the present invention.
    Type: Application
    Filed: July 3, 2020
    Publication date: November 17, 2022
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Daisuke HATANAKA, Tatsuro KANAKI, Hisato HAYASHI
  • Publication number: 20220306985
    Abstract: The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition wherein indeterminate structures are formed in a liquid medium, the structures are uniformly dispersed in the solution and substantially retain the cells and/or tissues without substantially increasing the viscosity of the solution, thus affording an effect of preventing sedimentation thereof, and the like
    Type: Application
    Filed: May 23, 2022
    Publication date: September 29, 2022
    Applicants: Nissan Chemical Industries, Ltd., Kyoto University
    Inventors: Taito NISHINO, Tatsuro KANAKI, Ayako OTANI, Koichiro SARUHASHI, Misayo Tomura, Takehisa IWAMA, Masato HORIKAWA, Norio NAKATSUJI, Tomomi OTSUJI
  • Publication number: 20220267480
    Abstract: The present invention provides a method capable of easily mixing any liquid containing a linking substance such as a divalent metal cation and the like with a liquid containing a particular compound at a high concentration, and capable of producing a liquid medium composition comprising fine structures dispersed therein, and a production device therefor and a kit therefor. The first liquid containing a particular compound is passed through a through-hole having a given cross-sectional area formed in a nozzle part at a given flow rate and injected into the second liquid at a given flow rate. By this simple operation, a structure in which the particular compound is bonded via the linking substance is formed, and the structure is preferably dispersed in a mixture of the both liquids.
    Type: Application
    Filed: May 11, 2022
    Publication date: August 25, 2022
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Hisato HAYASHI, Koichiro SARUHASHI, Tatsuro KANAKI
  • Patent number: 11384112
    Abstract: Provided is an artificial nucleoside or artificial nucleotide capable of composing an artificial oligonucleotide having superior nuclease resistance. The artificial nucleoside or artificial nucleotide is a compound represented by formula (I) or a salt thereof (wherein, Bx represents a pyrimidine base or purine base, R1, R2, R3 and R4 represent hydrogen atoms, C1-6 alkyl groups or the like, Y represents NR5R6 (wherein, R5 and R6, independently of each other, represent a hydrogen atom, C1-6 alkyl group or the like, or R5 and R6, together with a nitrogen atom bound thereto, form a 3- to 11-membered nitrogen-containing non-aromatic heterocyclic group) or an optionally substituted C2-9 aromatic heterocyclic group, Z1 and Z2 represent hydrogen atoms, hydroxyl group-protecting groups, phosphorous-containing groups or the like, and n represents an integer of 1 to 3).
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: July 12, 2022
    Assignees: TOKYO INSTITUTE OF TECHNOLOGY, NISSAN CHEMICAL CORPORATION
    Inventors: Kohji Seio, Yoshiaki Masaki, Keishi Yamamoto, Keita Yoshida, Yusuke Iriyama, Hiroyuki Nakajima, Tatsuro Kanaki
  • Patent number: 11371013
    Abstract: The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition wherein indeterminate structures are formed in a liquid medium, the structures are uniformly dispersed in the solution and substantially retain the cells and/or tissues without substantially increasing the viscosity of the solution, thus affording an effect of preventing sedimentation thereof, and the like.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: June 28, 2022
    Assignees: Nissan Chemical Industries, Ltd., Kyoto University
    Inventors: Taito Nishino, Tatsuro Kanaki, Ayako Otani, Koichiro Saruhashi, Misayo Tomura, Takehisa Iwama, Masato Horikawa, Norio Nakatsuji, Tomomi Otsuji
  • Patent number: 11345762
    Abstract: The present invention provides a method capable of easily mixing any liquid containing a linking substance such as a divalent metal cation and the like with a liquid containing a particular compound at a high concentration, and capable of producing a liquid medium composition comprising fine structures dispersed therein, and a production device therefor and a kit therefor. The first liquid containing a particular compound is passed through a through-hole having a given cross-sectional area formed in a nozzle part at a given flow rate and injected into the second liquid at a given flow rate. By this simple operation, a structure in which the particular compound is bonded via the linking substance is formed, and the structure is preferably dispersed in a mixture of the both liquids.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 31, 2022
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Hisato Hayashi, Koichiro Saruhashi, Tatsuro Kanaki
  • Publication number: 20220041971
    Abstract: A separation device for separating a solid separation target contained in a suspension obtained by suspension culture of adherent cells by using a fine scaffold material, and a separation method. The separation device has a separation chamber having a first chamber and a second chamber, and the first chamber and the second chamber are divided by a mesh structure for separation. The mesh structure for separation has mesh-holes with a predetermined size to suppress passage of the separation target, and a mesh structure for separation is configured in the separation chamber such that the liquid in the aforementioned suspension has a vertically upward directional component in the advancing direction of the liquid when the liquid passes through the mesh-holes.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 10, 2022
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Daisuke HATANAKA, Katsuhiko KIDA, Tatsuro KANAKI, Hisato HAYASHI
  • Publication number: 20210340491
    Abstract: The present invention provide a medium composition for suspension culture of an adherent cell, containing (1) a chitin nanofiber; and (2) a chitosan nanofiber or a polysaccharide.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 4, 2021
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Tatsuro KANAKI, Katsuhiko KIDA, Masataka MINAMI, Daisuke HATANAKA
  • Publication number: 20210254055
    Abstract: The invention provides a single-stranded oligonucleotide represented by the formula (I), wherein X and Y hybridize by a first nucleotide sequence portion and a second nucleotide sequence portion. X is composed of 7 to 100 nucleotides, contains at least one modified-nucleotide, and has a first nucleotide sequence capable of hybridizing with a second oligonucleotide. Y is composed of 4 to 100 nucleotides, enables hybridization with the above-mentioned first oligonucleotide, and has a second nucleotide sequence containing at least one ribonucleotide. At least one of the nucleotide sequences X, Xz and Y has an antisense sequence capable of hybridizing with a target RNA. At least one of L, Lx and Ly is a linking group that contains a non-nucleotide structure.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 19, 2021
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI, Masatoshi NIWA
  • Publication number: 20210188894
    Abstract: Provided is an artificial nucleoside or artificial nucleotide capable of composing an artificial oligonucleotide having superior nuclease resistance. The artificial nucleoside or artificial nucleotide is a compound represented by formula (I) or a salt thereof (wherein, Bx represents a pyrimidine base or purine base, R1, R2, R3 and R4 represent hydrogen atoms, C1-6 alkyl groups or the like, Y represents NR5R6 (wherein, R5 and R6, independently of each other, represent a hydrogen atom, C1-6 alkyl group or the like, or R5 and R6, together with a nitrogen atom bound thereto, form a 3- to 11-membered nitrogen-containing non-aromatic heterocyclic group) or an optionally substituted C2-9 aromatic heterocyclic group, Z1 and Z2 represent hydrogen atoms, hydroxyl group-protecting groups, phosphorous-containing groups or the like, and n represents an integer of 1 to 3).
    Type: Application
    Filed: February 17, 2017
    Publication date: June 24, 2021
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, NISSAN CHEMICAL CORPORATION
    Inventors: Kohji SEIO, Yoshiaki MASAKI, Keishi YAMAMOTO, Keita YOSHIDA, Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI
  • Publication number: 20210054377
    Abstract: The invention provides an antisense oligonucleotide reduced in toxicity. The antisense oligonucleotide has a central region, a 5?-side region and a 3?-side region, wherein the central region has a nucleotide (2?-3? bridged nucleotide) in which the 2?-position and the 3?-position of a sugar moiety are bridged and/or a non-bridged nucleotide (3?-position-modified non-bridged nucleotide) having a substituent at the 3?-position.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 25, 2021
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, NISSAN CHEMICAL CORPORATION
    Inventors: Yoshiaki MASAKI, Kohji SEIO, Atsushi INOUE, Yusuke IRIYAMA, Tatsuro KANAKI, Hiroyuki NAKAJIMA